| 新型抗抑郁药维拉唑酮的药理与临床评价 |
| |
| 引用本文： | 王来海,张瑞岭,李焕芬. 新型抗抑郁药维拉唑酮的药理与临床评价[J]. 中国新药杂志, 2011, 0(18) |
| |
| 作者姓名： | 王来海 张瑞岭 李焕芬 |
| |
| 作者单位： | 新乡医学院第二附属医院; |
| |
| 基金项目： | 河南省卫生科技创新型人才工程专项(2011-2015) |
| |
| 摘 要： | 维拉唑酮为一种双重作用机制的新型抗抑郁药,即选择性5羟-色胺(5-HT)再摄取抑制剂和5-HT1A受体部分激动剂,2011年1月21日获得美国食品药品管理局(FDA)批准,用于成人重症抑郁症(major depressive d isorder,MDD)的治疗。其常见不良反应包括腹泻、恶心、呕吐和失眠。文中对维拉唑酮的药理作用、药动学、临床评价、安全性以及药物相互作用等进行了综述。
|
| 关 键 词： | 维拉唑酮 抗抑郁药 5羟-色胺再摄取抑制剂 药理学 临床评价 |
Pharmacology and clinical evaluation of the new antidepressant drug vilazodone |
| |
| WANG Lai-hai,ZHANG Rui-ling,LI Huan-fen. Pharmacology and clinical evaluation of the new antidepressant drug vilazodone[J]. Chinese Journal of New Drugs, 2011, 0(18) |
| |
| Authors: | WANG Lai-hai ZHANG Rui-ling LI Huan-fen |
| |
| Affiliation: | WANG Lai-hai,ZHANG Rui-ling,LI Huan-fen(The Second Affiliated Hospital of Xinxiang Medical College,Xinxiang 453002,China) |
| |
| Abstract: | Vilazodone,a new type of antidepressant,possesses dual mechanism of action.It was approved for the treatment of major depressive disorder by FDA in January 21,2011.It is a selective serotonin(5-HT) reuptake inhibitor and a partial 5-HT1A receptor agonist.The most common adverse reactions of vilazodone are diarrhea,nausea,vomiting and insomnia.The pharmacology,pharmacokinetics,clinical evaluation,safety and drug interactions of vilazodone were reviewed in this paper. |
| |
| Keywords: | vilazodone antidepressant 5-HT reuptake inhibitor pharmacology clinical evaluation |
| 本文献已被 CNKI 等数据库收录！ |
|
